Chromosome 18q is lost a high proportion of colorectal and pancreatic cancers. Three candidate tumor suppressor genes, DCC, Smad4 and Smad2 have been identi®ed in this chromosome region. DCC and Smad4 aberrations have been previously identi®ed in pancreatic and colorectal tumors. The aim of this study was to compare the presence of concurrent genetic aberrations in DCC and neighboring Smad4 and Smad2 genes during colorectal and pancreatic distal dissemination. We have used a panel of orthotopically implanted colorectal and pancreatic xenografts and corresponding metastases. We have shown that while LOH at DCC locus occurred at a similar frequency in both tumors, diminished DCC protein expression was exclusively present in colorectal tumors harboring intragenic DCC LOH. In contrast, in pancreatic xenografts loss of DCC protein and mRNA expression was restricted to metastases. Smad4 gene aberrations were detected at a similar frequency in both tumors and were selected for during distal dissemination. Acquisition of alterations in both genes occurred independently. Our results suggest that both DCC and Smad4 contribute to pancreatic and colorectal distal dissemination. However, the role of DCC may dier between both tumor types. Oncogene (2000) 19, 546 ± 555.
Introduction
Previous studies have proved that chromosome 18q is lost in 80% of pancreatic (Hahn et al., 1995) and 60% of colorectal (Kern et al., 1989; Cho et al., 1994) cancers. Allelic losses of chromosome 18q may predict a poor outcome in patients of colorectal cancer (Jen et al., 1994; MartõÂ nez-LoÂ pez et al., 1998) initially attributed to diminished DCC expression (Shibata et al., 1996) . Three candidate tumor suppressor genes, DCC (Fearon et al., 1990) , Smad4 and Smad2 (Eppert et al., 1996; Riggins et al., 1996) have been cloned and identi®ed from this chromosome region.
The initial candidate gene in the 18q region, DCC, encodes for a transmembrane protein that might function as a receptor for the axonal chemoattractant nettrin-1 (Keino-Masu et al., 1996) . DCC gene is apparently involved in colorectal tumorigenesis (Cho et al., 1994; Shibata et al., 1996; Chen et al., 1999) , although controversial results have been reported (Fazeli et al., 1997; Fabre et al., 1999) . Several authors, using immunohistochemistry, have shown that DCC expression may be diminished in colorectal cancers (Goi et al., 1998; Schmitt et al., 1998) . However, Western blot analyses yielded contradictory results (Goi et al., 1998; Gotley et al., 1996) . On the other hand, loss of DCC mRNA expression is apparently common in human pancreatic primary tumors and cell lines (HoÈ hne et al., 1992; Simon et al., 1994) .
Smad4 and Smad2 genes encode for proteins that play an essential role in TGF-beta signaling pathways. Smad4 is structurally altered in a signi®cant proportion of human pancreatic Villanueva et al., 1998; BarberaÂ et al., 1999, unpublished) and colorectal carcinomas (Takagi et al., 1996; Thiagalingam et al., 1996; MacGrogan et al., 1997; Hoque et al., 1997) where it has been associated with its metastatic potential (Miyaki et al., 1999) . The increased susceptibility to colorectal cancer observed in Smad4/Apc compound mutant mice has reinforced the role of this gene in colorectal tumorigenesis (Takaku et al., 1998) . Finally, Smad2 gene mutations have been identi®ed in a small proportion of colorectal cancers (Eppert et al., 1996) and are apparently absent from pancreatic carcinomas (Villanueva et al., 1998) .
Few studies have attempted to assess the degree of genetic heterogeneity in the 18q21 locus in human tumors Kong et al., 1997; Ueda et al., 1997; Papadimitrakopoulou et al., 1998; Takei et al., 1998) . Using colorectal xenografts, it was shown that Smad4 may be the deletion target in one third of the tumors, and that DCC or a neighboring gene was the target in the remaining two thirds . No study has attempted to clarify this issue in pancreatic tumorigenesis.
The aim of this study was to compare the presence of concurrent genetic aberrations in DCC and neighboring Smad4 and Smad2 genes during colorectal and pancreatic tumor progression and dissemination. Our experimental strategy has combined: (i) genetic screening using, mainly, intragenic markers; (ii) mutation detection assays and mRNA and protein expression; and (iii) the use of orthotopically implanted xenografts (Fu et al., 1991; Reyes et al., 1996) that precludes the eect of contaminating normal tissue on genetic analysis and allows the reproduction of their distal dissemination patterns (Reyes et al., 1996; Villanueva et al., 1998) .
Results

Detection of DCC gene and protein aberrations in colorectal and pancreatic carcinomas
Colorectal carcinomas and corresponding metastases Thirteen perpetuated colorectal tumors were analysed (Table 1 and Figure 1 ). Ten of 13 (77%) colorectal xenografts were informative for at least one of the markers analysed. Intragenic allelic loss was found, in at least one marker, in ®ve of ten (50%) informative tumors; in three xenografts LOH was restricted to intragenic polymorphic markers, and in two coexisted with LOH at¯anking markers (Table 2 and Figure 2 ). In one additional case (NH 376) LOH was exclusively evidenced in a¯anking marker.
Western blot analyses using the three distinct antibodies yielded concordant results in all samples except one. Signal intensity was stronger with the Ab1-DCC antibody and, therefore, these results are shown ( Figure 2 ). Due to the low intensity observed with the other two antibodies the intensity of the signal was not quanti®ed. Only a complete absence of DCC signal in the Ab1-DCC Western blot was scored as a signi®cant diminution of DCC protein content. Normal colon mucosa and pancreatic tissue contained detectable amounts of DCC protein. Lack of detectable DCC protein was observed in four of the ®ve colorectal tumors harboring intragenic LOH at the DCC locus (Table 2 and Figure 2 ). The remaining case (NC492) was the only one showing discrepancies among the dierent antibodies. No signal was detected with G97-499 or the polyclonal antibodies, while an apparently lower intensity of the signal with the Ab1-DCC antibody was observed (Table 2 and Figure 2) . No dierences were observed in DCC protein content in orthotopic xenografts and corresponding primaries (Figure 2 ). Finally, DCC RT ± PCR products were evidenced in all xenografts during successive passages (Table 2) .
No additional loss of detectable DCC protein was evidenced in the 15 metastases originating from tumors containing DCC protein. Moreover, no additional LOH at the loci studied was evidenced (Table 2) . In all metastases, irrespective of their DCC protein content, DCC mRNA was detected (Table 2) . To con®rm that DCC mRNA detection was observed also human liver metastases, seven of these samples obtained from patients harboring colorectal carcinomas were also analysed. Accordingly, DCC mRNA ,8,11,15,17,20,21,22,23 and 27 followed well preserved patterms of dissemination. Yes, presence of dissemination; no, absenece of dissemination; Ð, not perpetuated. Tumors have been passaged for less than three times and have not been included in the present analysis.
c Tumors were obtained from Adenomatous Polyposis Coli patients. NC491P and NC491MH were primary and corresponding liver metastasis from the same patient. NC567T and NC567D were two synchronous carcinomas obtained from a patient belonging to a family meeting Amsterdam-like criteria was detected in all of them (data not shown). It must be emphasized that our RT ± PCR technique is not quantitative and relative reductions of mRNA cannot be evidenced.
Previous studies have shown discrepancies between Western blot and IHC analyses (Goi et al., 1998; Schmitt et al., 1998; and Gotley et al., 1996) , therefore IHC was performed (Figure 3 ). In nine cases (four negative and ®ve positive in Western analysis) a good correlation was observed between IHC and Western analyses using G97-499 Ab (Table 2 ). In all cases immunoreactivity was restricted to tumor cells and, in contrast with normal crypt cells, tumor cells show a distinct membrane pattern. No immunoreactivity was observed in the stroma. In the four remaining cases, DCC protein was detected in Western blot while no immunostaining was observed (Table 2) . It is of note that one of these cases (NC492) showed a lower DPC signal in the Western blot (Table 2 and Figure 2 ).0 0The availability of synchronous colorectal adenomas obtained from three of our cases allowed us to address the issue of timing of these alterations in early stages of the disease. Two of these carcinomas (NC492 and NC604) harbored intragenic LOH at the DCC locus (Table 2) . No intragenic LOH was observed in any of the 16 adenomas analysed (ten from NC492 and six from NC604). In these two cases, corresponding adenomas contained the same amount of DCC protein than their corresponding normal mucosa. In case NC604 no detectable DCC protein was evidenced both in primary and xenograft (Table 2 and Figure 2 ). In the remaining case (NC 548) neither adenomas nor carcinomas showed LOH or diminished DCC protein content (Figure 2 ). In all cases mRNA expression was observed as determined by RT ± PCR.
Pancreatic carcinomas and corresponding metastases
Similar to colorectal xenografts, LOH at DCC was evidenced in 50% (two of four) of the informative pancreatic xenografts (Table 3 and Figure 2 ). However, in contrast with colorectal tumors, no signi®cant decrease of DCC protein content was observed in the eight pancreatic xenografts analysed (Table 3 and Figure 2 ). In the three cases where corresponding primary was available (NP29, NP43, NP46), a perfect match was observed in DCC protein content of xenografts and primaries (data not shown). Finally, DCC RT ± PCR products were always detected. Three cell lines derived from xenografts (Villanueva et al., 1998) were also studied (NP9, NP18 and NP29). Interestingly, one of the three cell lines (NP29) showed a complete loss of DCC mRNA expression (data not shown) whereas the xenograft of origin contained a normal amount of DCC protein (Table 3) . Since tumors obtained after inoculation have not been analysed, it cannot be ruled out that this process is reversible. In sharp contrast with colonic samples, none of the normal pancreas and pancreatic xenografts showed DCC immunoreactivity (Table 3) .
A distinct pattern of DCC loss of expression was observed during pancreatic cancer dissemination when compared to colorectal cancer. Complete loss of DCC expression, as assessed by Western blot and also RT ± PCR, was observed in ten of 17 (59%) metastases analysed (Table 3 and Figure 2 ). Again all these alterations occurred without concomitant loss of the loci analysed. Additionally, in two of seven metastasisderived cell lines (GarciaÂ et al., submitted 1999) a complete lack of RT ± PCR products was observed (data not shown). In contrast with previous reports 
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wt Hematogenous and peritoneal dissemination (Simon et al., 1994) , no association was observed with loss of DCC expression and p53 gene status.
Detection of Smad4 gene aberrations in colorectal and pancreatic carcinomas
Colorectal carcinomas and corresponding metastases Three types of genetic aberrations in Smad4 gene were analysed: homozygous deletions, point mutations and loss of gene expression. Four out of 13 (31%) colorectal xenografts harbored structural alterations at Smad4 gene. Two xenografts contained homozygous deletions at Smad4, one of them with a concomitant LOH at this locus (D18S363) ( Table 2) . Accordingly, full-length Smad4 transcripts were absent in samples containing homozygous deletions (Table 2) . Two additional cases showed point mutations: NC393 harbored a point mutation (GGT to CGT) at nt 1284 that creates a single amino acid substitution at codon 386 of exon 9 (Table 2 and Figure 5) ; and NC544 contained a single base deletion at nt 444 (codon 106 of exon 2) that would predict a truncated protein. In these two cases full length mRNA was detected. It should be noted that in one additional case (NC501) LOH at¯anking marker D18S363 was evidenced in the absence of homozygous deletions.
No changes in Smad4 expression patterns were observed during serial passages of the tumors. Whenever Smad4 transcripts were detected in initial passages their presence was observed in the more advanced ones. Alternatively, no novel acquisition of Smad4 expression was detected. Since no semiquantitative analysis was performed we cannot rule out that diminished Smad4 expression occurred. Of the 18 metastases analysed, four (23%) contained additional losses of two or more Smad4 STSs markers with concomitant lack of expression as detected by RT ± PCR analyses (Table 2 and Figure 4 ). In the case (NC 393) where a point mutation was evidenced in the orthotopic xenografts, all metastases showed the same genetic alteration ( Figure 5 ) without acquiring additional losses (Table 2) . Two of the xenografts with corresponding adenomas available (NC548 and NC604) harbored homozygous deletions at the Smad4 gene. However, this type of genetic alterations could not be evidenced in primary adenocarcinomas or adenomas probably re¯ecting the presence of contaminating normal cells in the samples analysed. No attempt was made to search for Smad4 mutations in adenomas.
Pancreatic carcinomas and corresponding metastases Smad4 genetic analysis of this panel of pancreatic xenografts and of a more extended series of metastases has previously been reported (Villanueva et al., 1998) . We showed that two of the eight pancreatic xenografts harbored alterations in the Smad4 gene (homozygous deletion and one abnormal SSCP pattern). In addition, we also showed that, in contrast with colorectal xenografts, three pancreatic xenografts that retained all DNA markers analysed (NP9, NP40 and NP43) progressively lost Smad4 expression, as assessed by lack of RT ± PCR products, in advanced (more than three) passages in nude mice. Finally, and similar to what happened in colorectal tumors, one or more Smad4 STSs markers were lost in three of 17 (18%) metastases. Smad4 transcript was also absent from these samples (Table 3 ).
Smad4 and DCC aberrations are independent events
The combined analysis of primary tumors, orthotopically implanted human colorectal and pancreatic tumors and corresponding metastases has shown that Smad4 and DCC are independent genetic events. Alterations in DCC and/or Smad4 genes were detected in eight of 13 colorectal xenografts; only in one of them (NC 604) coexisted. Only three of eight pancreatic xenografts contained DCC and/or Smad4 genes; in one of them (NP 29) both alterations coexisted (Tables 2 and 3) .
Moreover, acquisition of Smad4 and DCC aberrations during distal dissemination are also independent areas. Additional Smad4 and/or DCC alterations were identi®ed in four of 18 (22%) metastases from Figure 4 Genetic aberrations and expression of the Smad4 and Smad2 genes in colorectal xenografts, corresponding metastases and primaries. RT ± PCR and STSs analyses are shown. Metastasis (PM2) obtained from colorectal xenograft NC397 acquired additional homozygous deletions of p128-N21 and DPC4 Exon 11 STS markers. Another metastasis (PM1) did not. Deletion restricted to p128-N21 marker was evidenced in xenograft NC604 and not in the corresponding primary tumor. Expression of Smad4 gene was lost whenever an homozygous deletion was evidenced. Note that co-ampli®cation of mouse DNA occurred in DPC4 Exon1 and Exon11 markers; SSCP analysis (on the right) allowed identi®cation of the human pattern. P53 RT ± PCR, as a control of RNA quality, is also shown. N, normal colorectal mucosa; X, xenograft; P, corresponding primary tumor; PM, PM1, PM2, peritoneal metastases; mouse, mouse colon; human, human colon colorectal xenografts and in 11 of 17 (65%) metastases from pancreatic xenografts. Concomitant alterations in both genes were observed in a minority (three of 35; 8.5%) of all metastases analysed. It is of note that only two metastases originating from the same pancreatic xenograft simultaneously acquired DCC and Smad4 aberrations. No point mutation or lack of expression was detected in the conserved domains of the Smad2 gene in any of the pancreatic and colorectal xenografts and metastases analysed (Tables 2 and 3 and Figure 4) .
Discussion
In the present study we have determined the relative contribution of three genes located at the 18q21 region (DCC, Smad2 and Smad4) to progression and dissemination of human colorectal and pancreatic tumors. We have combined the analysis of perpetuated orthotopic xenografts and corresponding metastases with studies on primary tumors. Early passages of orthotopic (implantation in the same organ of origin of the tumor) xenografts are close to their corresponding human primary tumors, have proved useful for the study of allelic losses or homozygous deletions (Hahn et al., 1995; Villanueva et al., 1998) , and facilitates the reproduction, in the experimental animal, of their distal dissemination patterns (Fu et al., 1991; Reyes et al., 1996; Villanueva et al., 1998) .
Previously, it has been suggested that DCC or a neighboring gene could be the target gene in the lost region at 18q21 in up to two-thirds of colorectal xenografts . In our study, we have evidenced the presence of intragenic LOH in 50% of all informative carcinomas. More importantly, an excellent correlation between undetectable DCC protein levels and intragenic DCC LOH suggesting this may be an important mechanism of DCC inactivation in these tumors and indirectly supporting the role of DCC in human colorectal tumorigenesis. Previous studies, utilizing Western blot analyses, have provided with contradictory results raising doubts about the reliability of these ®ndings (Gotley et al., 1996; Shibata et al., 1996; Goi et al., 1998) . We have obtained nearly identical results with three distinct antibodies strongly supporting the validity of our observations. Only one study has attempted to correlate DCC protein levels, assessed by IHC, with DCC LOH without conclusive feelings (Schmitt et al., 1998) . Discrepancies observed between DCC IHC and Western blot analyses (Gotley et al., 1996; Goi et al., 1998 and the present study) preclude their comparative analysis. It is also intriguing that DCC staining shows a membrane pattern in tumor cells while crypt cells depict a cytoplasmatic one. This may simply re¯ect dierences in the response of tumor cells in front of antigen retrieval methods. The lack of detectable DCC protein does not associate with absence of DCC mRNA. Previously, RT ± PCR analysis in colorectal cancer cells have provided controversial results (Itoh et al., 1993; Iino et al., 1994; Thiagalingam et al., 1996; Fabre et al., 1999) . The diculty in optimizing a robust RT ± PCR assay may account, in part, for these discrepancies (BarberaÂ et al., 1999, unpublished) .
DCC mRNA or protein expression has been shown to be either reduced (Iino et al., 1994; Goi et al., 1998) or maintained (Gotley et al., 1996) during colorectal distal dissemination. We observed no signi®cant additional decrease of DCC protein content or intragenic DCC LOH in metastases from colorectal xenografts. Interestingly, we have not observed DCC LOH or decreased DCC protein content in the adenomas analysed. These ®ndings suggest that decreases of DCC protein levels, when present, occur early after the appearance of the fully malignant phenotype in colorectal tumorigenesis and that they may not accumulate during distal dissemination.
Colorectal and pancreatic tumor cells share a similar pattern of genetic alterations (i.e. high incidence of K-ras and p53 mutations) (CapellaÂ et al., 1991; Peinado et al., 1993; Reyes et al., 1996) . Accordingly, diminished or absent DCC mRNA expression has been reported in the majority of human pancreatic cancer cells (Simon et al., 1994; BarberaÂ et al., 1999 unpublished) . In our study several dierences have become apparent, regarding DCC expression, between colorectal and pancreatic cancer cells: (i) DCC protein is detected in all pancreatic xenografts; (ii) no immunoreactivity is observed in Figure 5 SSCP/PCR and automatic sequencing of Smad4 in colorectal xenograft NC393. An abnormal mobility pattern is observed in xenograft (X) and peritoneal metastases (PM) in the SSCP analysis. Sequencing depicts a single base substitution at nt 1284 of exon nine of the Smad4 gene. N, corresponding colon mucosa; Gly, glycine, Arg, arginine Figure 6 Schematic representation of the extragenic and intragenic markers analysed at the 18q21 region according to data obtained from Fearon et al., 1990; Parry et al., 1991; Hahn et al., 1996 normal pancreas or pancreatic tumor cells perhaps re¯ecting dierences in the sensitivity of antigen retrieval methods between distinct tissues; and (iii) DCC expression is consistently lost in the majority of metastases of pancreatic xenografts even in the absence of concomitant LOH. These observations suggest that loss of DCC expression does indeed play a role in pancreatic cancer distal dissemination, where it probably is a late epigenetic event independent of intragenic LOH.
Smad2 and Smad4, known members of the signaling pathways of the TGF-b1, are close to the DCC locus and have been reported to be mutated in colorectal (Eppert et al., 1996; Takagi et al., 1996) and pancreatic BarberaÂ et al., 1999 unpublished) cancer cells. Our results suggest that the incidence and pattern of Smad4 structural alterations in colorectal xenografts is similar to the pancreatic ones (Villanueva et al., 1998) . Our ®ndings are in agreement with previous reports on colorectal xenografts or cell lines MacGrogan et al., 1997) or even primary tumors (Takagi et al., 1996; Miyaki et al., 1999) . Previously it was suggested that Smad4 might in¯uence the metastatic potential of colorectal tumors (Miyaki et al., 1999) . We have shown that Smad4 mutations can be acquired during distal dissemination of colorectal and pancreatic tumors, further supporting a signi®cant role of this gene in these carcinomas (Takaku et al., 1998) . Finally, Smad2 gene is unlikely to play a signi®cant role in colorectal or pancreatic tumorigenesis.
In colorectal and pancreatic cancer cells, Smad4 and DCC aberrations are independent genetic events, con®rming the genetic heterogeneity of the 18q21 locus in both tumors. While Smad4 plays a similar role in colorectal and pancreatic tumor progression and dissemination, some dierences become apparent regarding DCC. Our LOH and DCC protein studies retain DCC as a viable candidate for a target gene in this region in approximately half of colorectal tumors. However, interpretation of LOH should be cautious since loss of heterozygosity in neighboring or even intragenic markers may not always re¯ect the loss of a relevant gene (Gupta et al., 1997; Buuren-van Seggelen et al., 1998) . In pancreatic cancer, loss of DCC expression is more likely an epigenetic phenomenon that associates with the establishment of distal metastases and is independent of intragenic LOH. Finally, the presence of intragenic DCC LOH without concomitant DCC alterations may re¯ect the possibility that another tumor suppressor gene (Takei et al., 1998) , close to DCC gene, may be altered in pancreatic cancer cells.
Materials and methods
Animals
Four ± ®ve-week-old male nu/nu Swiss mice, weighing 18 ± 22 g (Ia-Credo Animaux de Laboratoire, L'Abresle, France) were used for tumor implantation. Animals were housed in a sterile environment; cages and water were autoclaved; bedding and food was gamma-ray sterilized.
Implantation and perpetuation of human colorectal cancer xenografts
Fresh surgical specimens of 27 human colorectal tumor were used (Table 1) : 22 primary tumors and ®ve metastases. None of the patients had received prior cytotoxic therapy. Tumor fragments were obtained in sterile conditions from dierent areas of the specimen and immediately placed in RPMI 1640 medium supplemented with penicillin, gentamicin and fungizone. Five nude mice were each implanted with two pieces of tumor, a total of ten pieces. Under general anesthesia, tumor pieces were anchored to the serosa of the caecum with a Prolene 6-0 suture (Fu et al., 1991) . After implantation mice were inspected twice a week. When no tumor growth was apparent, mice were sacri®ced 6 months after implantation. Successive passages were performed in two to ®ve animals according to time elapse for each tumor. To assess tumor dissemination pattern, in every passage at least two mice were kept alive until they were moribund. Sixteen of the 27 tumors (12 primaries and four metastases) ( Table 1 ) grew as orthotopic implants in nude mice. For every perpetuated colorectal xenograft, a big (2 ± 3 cm in diameter) solid mass (Figure 1 ) extensively replaced the mouse caecum, in some cases this caused intestinal obstruction or hemorrhage. A good correlation between the histological appearance of the primary and the perpetuated tumors in mice was evidenced. Time elapse between passages diered between tumors and remained constant through several passages for each tumor (Table 1) .
Human colorectal cancer samples
Thirteen colorectal xenografts perpetuated for more than four passages were included in the present analysis; early passages were studied (1 ± 4). Most (11 of 13) of the xenografts showed some type of distal dissemination pattern (Table 1 and Figure 1) . A total of 18 metastases obtained from ®ve perpetuated orthotopic xenografts were also analysed (Table 2) . Corresponding primary or metastatic tumors were also studied in nine cases (NC376, NC397, NC491T, NC419MH, NC492, NC501, NC544, NC604). In three cases (NC604, NC548 and NC492), two of them Adenomatous Polyposis Coli, a variable number (6 ± 10) of synchronous adenomas were also included. Normal mucosa was available from all cases. A total of 83 samples were analysed.
Human pancreatic cancer xenografts
Eight pancreatic cancer xenografts orthotopically implanted in nude mice, that retained the histological appearance of the primary tumors and a high degree of genetic stability regarding K-ras, p53 and p16 status (Reyes et al., 1996) , were analysed in early passages. A total of 17 metastases from dierent locations (Table 3 ) obtained during distal dissemination of four perpetuated tumors were also studied (Reyes et al., 1996) . Corresponding normal or metastatic tumors and microscopically normal pancreata were available for study in three cases (NP29, NP43 and NP46). A total of 35 samples were analysed.
Analysis of DCC aberrations
RT ± PCR Total RNA was extracted from cell pellets and tissues by a single-step method. Two mg of total RNA was reverse transcribed to cDNA as previously described (Villanueva et al., 1998) and a 233 bp fragment involving nt 986-1218, that includes ®ve and six, was ampli®ed using speci®c primers as described (Fearon et al., 1990) . The identity of the ampli®ed fragments was con®rmed by cycle sequencing using the AmpliCycle Sequencing Kit (Perkin Elmer, Branchburg, NJ, USA) following manufacturer's directions. Internal control for RNA quality was obtained with b-actin (data not shown) and p53 (Figure 4 ) gene sequences ampli®cation. No attempt was made to optimize the number of PCR cycles to be in the linear range and, therefore, no semiquantitative measurement of mRNA expression was performed. Failure to obtain a PCR product in three independent experiments in the presence of b-actin and p53 ampli®cation was scored as a complete absence of DCC transcripts. No concomitant mouse DCC mRNA ampli®cation was observed.
Protein analyses DCC protein expression was analysed by means of Western blotting and immunohistochemistry.
Western blot analysis Samples were frozen, lysed in 80 mM Tris-HCl (pH 6.8) containing 2% SDS, sonicated and ®nally resuspended in Laemmli buer. Fifty mg of protein were then electrophoresed using 6% SDS-polyacrylamide gel and transferred onto Immobilon P membranes (Millipore, Bedford, MA, USA). Western blotting was performed using three speci®c antibodies against DCC: (a) monoclonal antibody Ab1-DCC (Oncogene Science; dilution 1 : 200 for 2 h at room temperature) that recognizes the extracellular domain of the human DCC protein ; (b) monoclonal antibody G97-499 (Pharmingen, San Diego, CA, USA; dilution 1 : 250 for 2 h at room temperature) (Shibata et al., 1996) that recognizes the intracellular domain; and (c) a polyclonal antibody (a gift of M Fabre and FX Real; IMIM, Barcelona, dilution 1 : 1000 for 2 h at room temperature) (Fabre et al., 1999) that recognizes the intracellular domain. A similar amount of protein was transferred to the membrane as assessed by bactin Western blotting (data not shown). Speci®city of all Abs was tested in DCC-transferred HT-29 human colorectal cancer cells and the parental clone (Fabre et al., 1999) . DCC-transfected HT-29 cells and adult brain tissue were used as positive controls (Figure 2 ). DCC protein signal was detected with the three antibodies utilized, although the Ab1-DCC yielded the stronger signal (Figure 2) . No signal was observed in parental HT-29 cells and liver tissue. It is of note that no cross-reactivity was evidenced between mouse and human DCC.
Immunohistochemistry (IHC) IHC was performed on formalin-®xed paran-embedded tissues of xenografts. Fivemicron sections were dewaxed in xylene and dehydrated. Endogenous peroxidase activity was blocked with 0.03% hydrogen peroxide. Antigen retrieval was achieved by means of heat and incubation with 10 mM citric acid monophosphate buer (pH 6.0). Sections were initially incubated with the primary Mab antihumna DCC, clone G97-499 (Pharmingen, San Diego, CA, USA) at a dilution 1 : 200 for 2 h at room temperature (Shibata et al., 1996) . Then secondary Ab anti-mouse peroxidase-conjugated EnVision TM (Dako, Carpinteria, CA, USA) was added for 30 min at room temperature followed by the addition of DAB+ cromogen (Dako, Carpinteria, CA, USA). Hematoxylin was used for counterstaining. Human colon mucosa (Figure 3 ) and human fetal central nervous system were used as positive controls. Normal colonic mucosa displayed granular staining of the cytoplasm of a scarce number of crypt cells. Occasionally, some cytoplasmic staining was also observed in luminal cells, when mucin vacuoles were small. There was not detectable immunoreactivity in non-epithelial cells and no crossreactivity was apparent with neuroendocrine cells (data not shown). In human fetal tissues only few faintly positive cells were detected (data not shown).
Allelic LOH at DCC locus and neighboring regions LOH was studied by a combination of intragenic and¯anking markers. Three intragenic markers were used: two MspI polymorphisms (M2, M3) (Parry et al., 1991) and one VNTR (Maesawa et al., 1996) . Flanking extragenic markers D18S69 (telomeric) and D18S851 (centromeric) were also used ( Figure 6 ). All samples were ampli®ed with 50 ± 100 ng of genomic DNA in the presence of radioactive nucleotide ([ 32 P]dCTP, 2 mCi/PCR tube) in a mixture containing PCR buer. All reactions were performed in a thermal cycler for 35 cycles. In all experiments mice DNA were included. The PCR products were separated in a 6% polyacrylamide/urea gel and autoradiography was performed. For M2 and M3 polymorphism analysis, PCR products were digested with MspI enzyme and analysed in 10% polyacrylamide gel. Four of the 13 xenografts were shown to belong to the microsatellite instability mutator phenotype (MIN+) (data not shown). In these cases only those markers displaying clear cut LOH results were included.
Detection of Smad4 gene aberrations
Analysis of homozygous deletions or LOH of the Smad4 gene Four sequence-tagged site (STS) markers: DPC4Exon 1, c917-46-T7, p128-N21, DPC4Exon 11 and one intragenic microsatellite D18S363 were used ( Figure 6 ). All STSs were ampli®ed using 50 ng of genomic DNA in the presence of radioactive nucleotide ([ 32 P]dCTP, 2 mCi/PCR tube) as previously described (Villanueva et al., 1998) . A homozygous deletion was de®ned by the absence of PCR product in three independent experiments. DNA quality was tested by amplifying a 1.2 kb fragment of the p53 gene (Figure 4) . In all experiments controls for DNA contamination were included every other sample. Nude mice normal colon and pancreas were always included. Co-ampli®cation of mouse DNA was evidenced with markers DPC4 Exon 1 and DPC4 Exon 11; SSCP analysis allowed characterization of the human PCR product (Figure 4 ).
RT ± PCR assay and mutational analysis
The whole coding region of the Smad4 gene was ampli®ed in ®ve overlapped reactions after cDNA synthesis as described (Villanueva et al., 1998) . Mutational analysis of the Smad4 gene was performed by means of the SSCP method. As described for DCC RT ± PCR assay, no attempt was made to optimize PCR in the linear range to perform semiquantitative measurement of mRNA expression.
Analysis of Smad2 gene cDNA was obtained as described above and the coding regions of the conserved domains of SMAD2 protein were ampli®ed as previously reported (Riggins et al., 1996) . Mutational analysis was performed following essentially the same protocol used for the Smad4 gene analysis (Villanueva et al., 1998) .
Abbreviations IHC, immunohistochemistry; LOH, loss of heterozygosity; SSCP, single strand conformation polymorphism; STS, sequence-tagged site; Mab, monoclonal antibody.
